Effect of the quassinoids glaucarubolone and simalikalactone D on growth of cells permanently infected with feline and human immunodeficiency viruses and on viral infections

Life Sciences

Volumn 62, Issue 3, 1997, Pages 213-219

  James Morre D ^a   Zeichhardt, Heinz ^b   Maxeiner, Hans Günther ^b   Grünert, Hans Peter ^b   Sawitzky, Dirk ^b   Grieco, Paul ^c  

^a PURDUE UNIVERSITY   (United States)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c INDIANA UNIVERSITY   (United States)

Author keywords

Antiviral; Feline immunodeficiency virus; Glaucarubolone; HIV 1; NADH oxidase; Quassinoids; Simalikalactone D

Indexed keywords

ANTINEOPLASTIC AGENT; GLAUCARUBOLONE; QUASSINOID DERIVATIVE; SIMALIKALACTONE D; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL GROWTH; DRUG EFFECT; DRUG SCREENING; FELINE IMMUNODEFICIENCY VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALIGNANT TRANSFORMATION; NONHUMAN; RETROVIRUS INFECTION; VIRUS INFECTION;

ANIMALIA; FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0031566009     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(97)01089-8     Document Type: Article

References (14)

1. D. J. MORRÉ, L.-Y. WU and D. M. MORRÉ, Biochim. Biophys. Acta 1236 237-243 (1995).
2. D. J. MORRÉ, P.-J. CHUEH and D. M. MORRÉ, Proc. Natl. Acad. Sci. U.S.A. 92 1831-1835 (1995).
3. D. J. MORRÉ, R. MERRIMAN, L. R. TANZER, L.-Y. WU, D. M. MORRÉ and W. C. MACKELLAR, Protoplasma 184 203-208 (1995).
4. D. J. MORRÉ, E. JACOBS, M. SWEETING, R. DE CABO and D. M. MORRÉ, Biochim. Biophys. Acta, in press.
5. D. J. MORRÉ, P. A. GRIECO and D. M. MORRÉ, Life Sciences, in preparation.
6. J. POLONSKY, Fortschr. Chem. Org. Naturst. 30 101-150 (1973).
7. J. M. CASSADY and M. SUFFNESS, Anticancer Agents Based on Natural Product Models, Academic Press, New York (1980).
8. A. PIERRE, M. ROBERT-GÉRCO, C. TEMPÊTE, and J. POLONSKY, Biochem. Biophys. Res. Comm. 93 675-686 (1980).
9. F. A. VALERIOTE, T. H. CORBETT, P. A. GRIECO, E. D. MOHER, J. L. COLLINS and T. J. FLECK, J. Exp. Therap. Oncol., in press.
10. R. L. TALBOTT, E. E. SPARGER, K. M. LOVELACE, W. M. FILCH, N. C. PEDERSEN, P. A. LUCICO and J. H. ELDER, Proc. Natl. Acad. Sci. USA 86 5743-5747 (1989).
11. T. R. PHILLIPS, R. L. TALBOTT, C. LAMONT, S. MUIR, K. LOVELACE and J. H. ELDER, J. Virol. 64 4605-4613 (1990).
12. A. J. JAPOUR, D. L. MAYERS, V. A. JOHNSON, D. R. KURITZKES, L. A. BECKETT, J.-M. ARDUINO, J. LANE, R. J. BLACK, P. S. REICHELDERFER, R. T. D'AQUILA and C. S. CRUMPACKER, Antimicrob. Ag. and Chemother. 37 1095-1101 (1993).
13. M. J. O'NIELL, D. H. BRAY, P. BOARDMAN, J. D. PHILLIPSON, D. C. WARHURST, W. PETERS, and M. SUFFNESS, Antimicrob. Ag. Chemother. 30 101-104 (1986).
14. T. A. GEISSMAN, Ann. Rev. Pharmaol. 4 305-316 (1964)